Fidelity Investments’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.8M | Buy |
209,370
+85,039
| +68% | +$4.33M | ﹤0.01% | 2022 |
|
|
2025
Q4 | $6.18M | Buy |
124,331
+23,894
| +24% | +$1.16M | ﹤0.01% | 2214 |
|
|
2025
Q3 | $4.8M | Buy |
100,437
+19,584
| +24% | +$789K | ﹤0.01% | 2254 |
|
|
2025
Q2 | $2.55M | Buy |
80,853
+3,238
| +4% | +$104K | ﹤0.01% | 2408 |
|
|
2025
Q1 | $2.54M | Buy |
77,615
+7,174
| +10% | +$254K | ﹤0.01% | 2369 |
|
|
2024
Q4 | $2.55M | Buy |
70,441
+53,538
| +317% | +$1.89M | ﹤0.01% | 2366 |
|
|
2024
Q3 | $527K | Buy |
16,903
+8,499
| +101% | +$265K | ﹤0.01% | 2830 |
|
|
2024
Q2 | $225K | Buy |
8,404
+409
| +5% | +$11.9K | ﹤0.01% | 2989 |
|
|
2024
Q1 | $273K | Buy |
7,995
+110
| +1% | +$3.27K | ﹤0.01% | 2923 |
|
|
2023
Q4 | $228K | Buy |
7,885
+173
| +2% | +$4.59K | ﹤0.01% | 2928 |
|
|
2023
Q3 | $213K | Sell |
7,712
-8,538
| -53% | -$260K | ﹤0.01% | 2878 |
|
|
2023
Q2 | $488K | Sell |
16,250
-651
| -4% | -$22.8K | ﹤0.01% | 2668 |
|
|
2023
Q1 | $612K | Buy |
16,901
+8,277
| +96% | +$318K | ﹤0.01% | 2628 |
|
|
2022
Q4 | $308K | Sell |
8,624
-28,175
| -77% | -$979K | ﹤0.01% | 2875 |
|
|
2022
Q3 | $1.25M | Buy |
36,799
+519
| +1% | +$16.9K | ﹤0.01% | 2548 |
|
|
2022
Q2 | $1.05M | Sell |
36,280
-6,229
| -15% | -$178K | ﹤0.01% | 2661 |
|
|
2022
Q1 | $1.37M | Sell |
42,509
-211,392
| -83% | -$6.48M | ﹤0.01% | 2704 |
|
|
2021
Q4 | $7.4M | Sell |
253,901
-50,512
| -17% | -$1.53M | ﹤0.01% | 2233 |
|
|
2021
Q3 | $8.12M | Sell |
304,413
-935,682
| -75% | -$25.1M | ﹤0.01% | 2197 |
|
|
2021
Q2 | $38.2M | Buy |
1,240,095
+434,521
| +54% | +$13.3M | ﹤0.01% | 1560 |
|
|
2021
Q1 | $21.1M | Buy |
805,574
+246,375
| +44% | +$6.89M | ﹤0.01% | 1785 |
|
|
2020
Q4 | $14.1M | Buy |
559,199
+425,790
| +319% | +$9.16M | ﹤0.01% | 1850 |
|
|
2020
Q3 | $2.78M | Sell |
133,409
-124
| -0.1% | -$2.81K | ﹤0.01% | 2226 |
|
|
2020
Q2 | $3.17M | Buy |
133,533
+4,806
| +4% | +$106K | ﹤0.01% | 2175 |
|
|
2020
Q1 | $2.32M | Sell |
128,727
-335,787
| -72% | -$7.06M | ﹤0.01% | 2159 |
|
|
2019
Q4 | $11M | Sell |
464,514
-43,514
| -9% | -$1.06M | ﹤0.01% | 1811 |
|
|
2019
Q3 | $14M | Sell |
508,028
-152,329
| -23% | -$4.51M | ﹤0.01% | 1710 |
|
|
2019
Q2 | $21.9M | Sell |
660,357
-76,711
| -10% | -$2.63M | ﹤0.01% | 1588 |
|
|
2019
Q1 | $25.8M | Sell |
737,068
-1,345,247
| -65% | -$50.1M | ﹤0.01% | 1478 |
|
|
2018
Q4 | $69.2M | Sell |
2,082,315
-289,006
| -12% | -$12.4M | 0.01% | 1012 |
|
|
2018
Q3 | $119M | Buy |
2,371,321
+1,430,021
| +152% | +$70.6M | 0.01% | 879 |
|
|
2018
Q2 | $56.3M | Buy |
941,300
+894,459
| +1,910% | +$46.3M | 0.01% | 1228 |
|
|
2018
Q1 | $2.15M | Sell |
46,841
-6,759
| -13% | -$282K | ﹤0.01% | 2349 |
|
|
2017
Q4 | $2.14M | Sell |
53,600
-12,300
| -19% | -$486K | ﹤0.01% | 2344 |
|
|
2017
Q3 | $2.64M | Sell |
65,900
-38,200
| -37% | -$1.65M | ﹤0.01% | 2281 |
|
|
2017
Q2 | $4.49M | Hold |
104,100
| – | – | ﹤0.01% | 2195 |
|
|
2017
Q1 | $3.26M | Sell |
104,100
-38,800
| -27% | -$1.04M | ﹤0.01% | 2250 |
|
|
2016
Q4 | $3.61M | Sell |
142,900
-420,400
| -75% | -$9.39M | ﹤0.01% | 2264 |
|
|
2016
Q3 | $13.9M | Sell |
563,300
-509,300
| -47% | -$11.5M | ﹤0.01% | 1855 |
|
|
2016
Q2 | $21.8M | Sell |
1,072,600
-189,100
| -15% | -$3.35M | ﹤0.01% | 1631 |
|
|
2016
Q1 | $19.2M | Buy |
1,261,700
+823,000
| +188% | +$10.7M | ﹤0.01% | 1679 |
|
|
2015
Q4 | $5.9M | Buy |
438,700
+200
| +0% | +$3.09K | ﹤0.01% | 2145 |
|
|
2015
Q3 | $6.15M | Sell |
438,500
-14,500
| -3% | -$270K | ﹤0.01% | 2116 |
|
|
2015
Q2 | $7.69M | Buy |
+453,000
| New | +$6.45M | ﹤0.01% | 2111 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Fidelity Investments's SUPN Position: Q1 2026 in Review
Fidelity Investments increased its Supernus Pharmaceuticals (SUPN) stake by 68% in Q1 2026, buying an estimated $4.33M and bringing the position to 209,370 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2022.
Fidelity Investments first reported a position in SUPN in Q2 2015 and has held it in 44 quarters since. The position peaked at $119M in Q3 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Fidelity Investments held 209,370 shares of Supernus Pharmaceuticals worth $10.8M as of Q1 2026.
- Fidelity Investments bought 85,039 Supernus Pharmaceuticals shares in Q1 2026, an estimated $4.33M.
- Supernus Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2022 holding.
- Fidelity Investments first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
- Fidelity Investments's Supernus Pharmaceuticals position peaked at $119M in Q3 2018.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.